Reply to E. Ritchie et al

Affiliations

¹ Aaron N. Winn, University of North Carolina at Chapel Hill, Chapel Hill, NC; Nancy L. Keating, Harvard Medical School and Brigham and Women's Hospital, Boston, MA; and Stacie B. Dusetzina, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC.

Comment

Aaron N Winn et al. J Clin Oncol. 2017.

. 2017 May 20;35(15):1745-1746.

doi: 10.1200/JCO.2016.72.0037. Epub 2017 Feb 13.

¹ Aaron N. Winn, University of North Carolina at Chapel Hill, Chapel Hill, NC; Nancy L. Keating, Harvard Medical School and Brigham and Women's Hospital, Boston, MA; and Stacie B. Dusetzina, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC.

No abstract available

Comment on

Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN, Keating NL, Dusetzina SB. Winn AN, et al. J Clin Oncol. 2016 Dec 20;34(36):4323-4328. doi: 10.1200/JCO.2016.67.4184. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27998234 Free PMC article.
Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia.
Ritchie EK, Guerin A, Wolff J, Joseph G. Ritchie EK, et al. J Clin Oncol. 2017 May 20;35(15):1744-1745. doi: 10.1200/JCO.2016.72.0011. Epub 2017 Feb 13. J Clin Oncol. 2017. PMID: 28524780 No abstract available.